These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 27021903

  • 1. Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    Li X, Shen B, Chen Q, Zhang X, Ye Y, Wang F, Zhang X.
    BMC Cancer; 2016 Mar 28; 16():251. PubMed ID: 27021903
    [Abstract] [Full Text] [Related]

  • 2. [Construction and expression of recombinant cecropin B-binding site of luteinizing hormone releasing hormone gene and its anticancer function].
    Li XY, Li HL, Zheng GY.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul 28; 42(7):477-81. PubMed ID: 17961339
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2002 Sep 28; 187(3):528-37. PubMed ID: 12237622
    [Abstract] [Full Text] [Related]

  • 4. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.
    Fertil Steril; 2005 Apr 28; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [Abstract] [Full Text] [Related]

  • 5. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2004 Oct 28; 191(4):1164-72. PubMed ID: 15507937
    [Abstract] [Full Text] [Related]

  • 6. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov 28; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 7. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Nov 28; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 8. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C, Völker P, Emons G.
    Endocrinology; 2001 Jun 28; 142(6):2369-80. PubMed ID: 11356684
    [Abstract] [Full Text] [Related]

  • 9. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV.
    J Clin Endocrinol Metab; 1993 Dec 28; 77(6):1458-64. PubMed ID: 8263128
    [Abstract] [Full Text] [Related]

  • 10. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A, Schally AV.
    Biol Reprod; 2005 Nov 28; 73(5):851-9. PubMed ID: 16033997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O.
    Arch Gynecol Obstet; 2012 Aug 28; 286(2):437-42. PubMed ID: 22555802
    [Abstract] [Full Text] [Related]

  • 15. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J, Emons G, Pinski J, Schally AV.
    Expert Opin Investig Drugs; 2012 Jun 28; 21(6):891-9. PubMed ID: 22577891
    [Abstract] [Full Text] [Related]

  • 16. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H.
    Anticancer Drugs; 2001 Jan 28; 12(1):71-8. PubMed ID: 11272290
    [Abstract] [Full Text] [Related]

  • 17. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
    Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, Harda K, Schally AV, Halmos G.
    Eur J Pharm Sci; 2018 Oct 15; 123():371-376. PubMed ID: 30076951
    [Abstract] [Full Text] [Related]

  • 18. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A.
    Anticancer Drugs; 2002 Oct 15; 13(9):949-56. PubMed ID: 12394258
    [Abstract] [Full Text] [Related]

  • 19. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Fister S, Günthert AR, Emons G, Gründker C.
    Cancer Res; 2007 Feb 15; 67(4):1750-6. PubMed ID: 17308117
    [Abstract] [Full Text] [Related]

  • 20. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.
    Oncol Rep; 2011 May 15; 25(5):1481-7. PubMed ID: 21331448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.